Olivia Munn has come a long way with her personal experience of breast cancer. Having informed the world of her diagnosis in ...

The 'Your Friends & Neighbors' star said she and her mom were there for each other for both of their double mastectomy surgeries: "There's something about watching a loved one go through it that is ...

The combination of trastuzumab deruxtecan with pertuzumab shows promise as a standard of care for HER2-positive advanced breast cancer.

Currently, evaluating HER2 status prior to first-line treatment is standard, Shitara said, to identify patients eligible for Herceptin. But, reassessing HER2 status in later lines isn't standard ...

Herceptin is approved for the treatment of early stage breast cancer that is H uman E pidermal growth factor R eceptor 2 -positive (HER2-positive) and has spread into the lymph nodes, or is HER2 ...

2. The addition of pyrotinib (Jiangsu Hengrui Therapeutics) to first-line trastuzumab (Herceptin, Genentech) and docetaxel improved PFS among patients with HER2-positive metastatic breast cancer.

Background and methods Standard neoadjuvant regimens for HER2-positive breast cancer include trastuzumab (Herceptin, Genentech), pertuzumab (Perjeta, Genentech) and chemotherapy.

The reason for that is they tried other HER2-directed drugs like herceptin [trastuzumab] and lapatinib [Tykerb] in the past, and it didn't work in prostate cancer. Because it's not a mutation or ...

The 420 mg strength of Hercessi, a biosimilar to Herceptin, is used to treat HER2-overexpressing breast and gastric or gastroesophageal junction adenocarcinoma.

Accord BioPharma's 420 mg strength Hercessi (trastuzumab-strf), a biosimilar to Herceptin, gains FDA approval to treat HER2-overexpressing breast cancer and gastric cancer.

Patients with HER2-positive breast cancer treated with the biosimilar trastuzumab-dkst experienced similar adverse events and well-being as those treated with the originator drug (Herceptin), ...